Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperTong‐Yuan Yang, Vibha Jawa, LiNa Loo et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 113
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)Bart Corsaro, Meina Liang, Tong‐Yuan Yang et al.|Bioanalysis|2021Cited by 60
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry PerspectiveHardik Mody, Vijay Upreti, K. OGASAWARA et al.|Clinical Pharmacology & Therapeutics|2023Cited by 26
Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirementsManuela Braun, Mark Milton, Claudia Lange et al.|Molecular Therapy — Methods & Clinical Development|2024Cited by 25
PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position PaperUma Kavita, Nagendra Chemuturi, Kefeng Sun et al.|The AAPS Journal|2023Cited by 17